ABSTRACT
Aim To examine ABO and Rh blood group distribution in COVID-19 related deaths considering demographics and pathological conditions.
Materials and Methods We conducted a retrospective study at the University Hospital Centre Split, Croatia, that included 245 COVID-positive individuals that died from April 8, 2020, to January 25, 2021. From the hospital database, we extracted data on their blood groups, demographics, and pre-existing comorbidities. To compare findings with the general population, we used information from collected blood group donations (n = 101357) and statistical reports of non-COVID deaths from 2019 (n = 4968).
Results The proportion of males was significantly higher in analyzed subjects than in non- COVID deaths from 2019 (63.7% vs. 48.9%, P < 0.001), while the proportion of older individuals did not differ (P = 0.8). The most common pre-existing diseases were hypertension (59.6%), diabetes (37.1%), heart failure (28.8%), digestive disorder (26.5%), and solid tumor (21.6%). The ABO distribution in the deceased and donors’ group showed statistically significant differences, with the higher prevalence of A/AB group and lower prevalence of 0, but with individual differences significant only for AB and non-AB groups. There was a significantly reduced proportion of females within the deceased with group 0 (P = 0.014) and a higher proportion of AB individuals with coronary heart disease (P = 0.024), while other differences were not significant.
Conclusion The study confirmed a higher risk of death in male individuals. The lower proportion of type 0 in deceased individuals was more pronounced in females, implying that group 0 is not necessarily an independent protective factor. Among analyzed comorbidities, coronary heart disease was identified as a potential risk factor for AB individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding recieved.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethical committee of University Hospital Centre Split on June 15, 2020 (500-03/20-01/09; 2181-147-01/06/M.S.-20-12).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* IB and IJ should be considered joint first author.
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
